Siemens Healthineers: New CTO Appointment and Diagnostics Overhaul Signal Turnaround Attempt

Siemens Healthineers shares gain 3% ahead of Q2 results, as analysts eye recovery from 52-week lows, with AI leadership change, tariff headwinds, and radiopharma expansion in focus.

The medical technology group Siemens Healthineers is attempting to navigate a path through turbulent waters, with its share price showing tentative signs of recovery ahead of second-quarter results due on Thursday. The stock climbed more than 3% on Wednesday to €36.14, pulling away from the 52-week low of €33.80 touched in late April. On a weekly basis, the gain stretches to roughly 4%, offering investors a glimmer of hope after a bruising period that has left the shares down nearly 19% year-to-date.

Analysts remain broadly constructive on the stock, with a median price target of €53.06 and some houses such as Barclays pencilling in as much as €55. The current floor around €33.24 is being watched closely by market technicians as a potential base from which a sustained recovery could build.

A new face in the C-suite

From June, Martin Stumpe will take over as Chief Technology Officer, replacing Peter Schardt after seven years in the role. The former Danaher and Google executive has been tasked with accelerating the company’s artificial intelligence agenda, particularly around digital patient models designed to deliver more precise diagnoses. The appointment signals a strategic pivot toward AI-driven healthcare solutions at a time when the group is grappling with operational headwinds on multiple fronts.

Tariffs, currency, and China weigh heavy

The immediate challenges are substantial. US tariffs are expected to hammer the full-year operating result by €400 million, while negative currency effects add further pressure. Management has already trimmed its forecast for adjusted earnings per share to a range of €2.20 to €2.40. For the second quarter, which ended in March, analysts anticipate a modest revenue increase to just over €5.9 billion, with earnings per share edging up to €0.50.

China remains a particular sore spot. A government anti-corruption campaign and tighter procurement rules have weighed heavily on the diagnostics division, raising questions about whether the unit has found a floor. The company is betting on automation to turn things around, investing heavily in robotic production lines that apply security features such as serial numbers and matrix codes to packaging. The move is partly a response to stricter EU regulations on drug safety and partly a bid to protect market share in a global market for counterfeit health products estimated at $75 billion.

Radiopharma push and the €14 billion debt dilemma

On the strategic front, the group is expanding its radiopharmaceuticals business. A new supply agreement with Radiopharm Theranostics will secure production of an imaging agent for an upcoming US approval study, after the FDA granted the drug fast-track status for diagnosing brain metastases.

But the structural elephant in the room remains the planned separation from parent Siemens. The spin-off, which would distribute 30% of Healthineers shares to Siemens shareholders and reduce the parent’s stake to below 20%, is tentatively scheduled for a shareholder vote at the February 2027 annual general meeting. A key obstacle is the roughly €14 billion debt pile, currently guaranteed by Siemens. Post-separation, Healthineers would have to shoulder that burden alone.

For now, all eyes are on Thursday morning’s quarterly numbers. The market will be looking for evidence that the diagnostics unit in China is stabilising and that operating margins can withstand the tariff onslaught. If management confirms its full-year guidance, the nascent recovery in the share price could gain further traction.